TY - JOUR
T1 - Acyl CoA binding protein (ACBP)
T2 - an autophagy checkpoint that can be targeted for improving cancer immunosurveillance
AU - Montégut, Léa
AU - Martins, Isabelle
AU - Kroemer, Guido
N1 - Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Acyl CoA binding protein (ACBP) encoded by DBI is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in Molecular Cancer that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.
AB - Acyl CoA binding protein (ACBP) encoded by DBI is a tissue hormone that limits autophagy in multiple cell types, hence acting as an extracellular autophagy checkpoint. We recently reported in Molecular Cancer that monoclonal antibodies neutralizing ACBP improve immunosurveillance of breast and lung carcinomas. Moreover, ACBP neutralization improves the outcome of neoadjuvant chemoimmunotherapy with PD-1 blockade in preclinical models.
KW - Caloric restriction mimetics
KW - chemotherapy
KW - immune checkpoint inhibitor
KW - immunotherapy mammary carcinoma
KW - non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85206051081&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2024.2413200
DO - 10.1080/2162402X.2024.2413200
M3 - Letter
C2 - 39381588
AN - SCOPUS:85206051081
SN - 2162-4011
VL - 13
JO - OncoImmunology
JF - OncoImmunology
IS - 1
M1 - 2413200
ER -